



CIN No. : L24239DL2004PLC125888

## AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Ref: Akums/Exchange/2024-25/19

October 9, 2024

To,  
The Listing Department  
National Stock Exchange of India Ltd  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E),  
Mumbai - 400 051

To,  
The Listing Department  
BSE Limited  
25th Floor, New Trading Ring,  
Rotunda Building, Phiroze Jeejeebhoy  
Towers, Dalal Street, Fort, Mumbai - 400  
001

Symbol: AKUMS

Scrip Code: 544222

Sub: **Launch of Dual Action Heartburn Relief Chewable Tablet**

Respected Sir/Mam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Akums Drugs & Pharmaceuticals Limited ("the Company") is pleased to announce the launch of its new product Famotidine, Calcium Carbonate and Magnesium Hydroxide in the Indian market.

This product is categorized as Antacids, Antiflatulents and Anti-Ulcerants and this product will cater to the Indian domestic market.

This product launch marks a step in commitment to innovation and providing high-quality healthcare solutions to our customers. We believe that new products will enhance our product portfolio and contribute positively to the Company's growth trajectory.

This disclosure is being made in compliance with aforesaid SEBI regulations.


This is for your kind information and record.

Thanking You

Your faithfully

For Akums Drugs and Pharmaceuticals Limited

Dharamvir Malik  
Company Secretary & Compliance Officer



ISO 9001 : 2015  
ISO 14001 : 2015  
ISO 17025 : 2005 (NABL)

WHO-GMP  
US : NSF  
H A C C P

